{
  "docId": "019de072-b09f-7797-83e5-c925df87e1b3",
  "docSlug": "fb96dc8e32131cd826524e728a742819",
  "documentTitle": "Compass Therapeutics | Investor Presentation Deck | 36 slides",
  "authorId": "compass-therapeutics",
  "authorName": "Compass Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 17,
  "pageCount": 36,
  "prevPage": 16,
  "nextPage": 18,
  "slideType": "problem_statement",
  "function": "frame_problem",
  "density": "dense",
  "nDataPoints": 25,
  "notes": "The slide highlights the limited progression-free survival (PFS) with a red box around the PFS column.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-b09f-7797-83e5-c925df87e1b3/17",
  "deckHref": "/decks/019de072-b09f-7797-83e5-c925df87e1b3",
  "deckJsonHref": "/decks/019de072-b09f-7797-83e5-c925df87e1b3.json",
  "deckAnchorHref": "/decks/019de072-b09f-7797-83e5-c925df87e1b3#slide-17",
  "components": [
    {
      "bbox": {
        "h": 0.04,
        "w": 0.75,
        "x": 0.06,
        "y": 0.85
      },
      "kind": "disclaimer",
      "text": "*OS (mo) reported from He et al., and ORR (%) reported from Paule et al. and Fornaro et al. are corrected.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f3816659-fd8d-4078-8bfa-9c6bc0883257",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.86,
        "x": 0.07,
        "y": 0.18
      },
      "kind": "paragraph",
      "text": "Historical data of outcomes in 2L chemo-based therapies after gemcitabine/plat-based combo therapy failure result in dismal outcomes with limited progression free survival:",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "990daa77-483c-41c8-bd77-5e598262810c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.35,
        "x": 0.51,
        "y": 0.78
      },
      "kind": "source-note",
      "text": "Source: Ahn and Bekaii-Saab 2017*",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2888f905-0aed-4f93-9a6e-f7a07e4e8871",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.43,
        "w": 0.88,
        "x": 0.06,
        "y": 0.32
      },
      "kind": "table",
      "text": "Author, Treatment, Phase, No. of patients, PFS (mo), OS (mo), ORR (%), He et al., FOLFOX-4, II, 37, 3.1, 6.9, 21.6, Paule et al., Gem/oxa + cetuximab, II, 9, 4.0, 7.0, 11.0, Sasaki et al., Irinotecan, II, 13, 1.8, 6.7, 7.7, Suzuki et al., S-1, II, 40, 2.5, 6.8, 7.5, Fornaro et al., Gem combination, Retrospective, 174, 3.0, 6.6, 3.4",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fd429c90-1da9-474a-8bb8-55c85ee2ff75",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.64,
        "x": 0.18,
        "y": 0.05
      },
      "kind": "title",
      "text": "Unmet Need for Second Line Therapies for Cholangiocarcinoma",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1400beee-aeb8-4b5b-9ab0-d1298743167e",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 17,
      "from": 6,
      "beatId": "4553c68f-c8a6-4cb5-9d28-9bc65dfd58fa",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Problem",
      "beatSlug": "problem-agitate-solution-problem-identify-pain",
      "evidence": "Slides 6-17 identify the problem, highlighting the unmet needs in BTC treatment.",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    },
    {
      "to": 24,
      "from": 16,
      "beatId": "f6eca836-c306-461a-9e22-743547581023",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Agitate",
      "beatSlug": "problem-agitate-solution-agitate-make-it-worse",
      "evidence": "Slides 16-24 agitate the problem, emphasizing the limitations of current treatments.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    }
  ],
  "loops": [
    {
      "to": 24,
      "from": 16,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "05173e5b-462d-46a8-b79a-b596b9de2b77",
      "evidence": "Slides 16-24 highlight the limitations of current treatments, implying the cost of inaction.",
      "position": 0,
      "objective": "What is the cost of not addressing the unmet needs in BTC treatment?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}